Journal of Menopausal Medicine

The Korean Society of Menopause (대한폐경학회)
권호 표지
DOI QR코드

DOI QR Code

Establishment of Effective Mouse Model of Premature Ovarian Failure Considering Treatment Duration of Anticancer Drugs and Natural Recovery Time

  • Lee, Eun hee (Department of Obstetrics and Gynecology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Han, Si Eun (Department of Obstetrics and Gynecology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Park, Min Jung (The Korea Institute for Public Sperm Bank) ;
  • Kim, Hyeon Jung (The Korea Institute for Public Sperm Bank) ;
  • Kim, Hwi Gon (Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Kim, Chang Woon (Department of Obstetrics and Gynecology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Joo, Bo Sun (The Korea Institute for Public Sperm Bank) ;
  • Lee, Kyu Sup (Department of Obstetrics and Gynecology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine)
  • Received : 2018.08.15
  • Accepted : 2018.09.23
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Objectives: This study was aimed to establish the most effective premature ovarian failure (POF) mouse model using Cyclophosphamide (CTX), busulfan (Bu), and cisplatin considering treatment duration of anticancer drugs and natural recovery time. Methods: POF was induced by intraperitoneally injecting CTX (120 mg/kg)/Bu (12 mg/kg) for 1 to 4 weeks or cisplatin (2 mg/kg) for 3 to 14 days to C57BL/6 female mice aged 6 to 8 weeks. Controls were injected with equal volume of saline for the same periods. Body weight was measured every week, and ovarian and uterine weights were measured after the last injection of anticancer drug. To assess ovarian function, POF-induced mice were superovulated with pregnant mare serum gonadotropin and human chorionic gonadotropin, and then mated with male. After 18 hours, zygotes were retrieved and cultured for 4 days. Finally, the mice were left untreated for a period of times after the final injection of anticancer drug, and the time for natural recovery of ovarian function was evaluated. Results: After 2 weeks of CTX/Bu injection, ovarian and uterine weights, and ovarian function were decreased sharply. Cisplatin treatment for 10 days resulted in a significant decrease in ovarian and uterine weight, and ovarian function. When POF was induced for at least 2 weeks for CTX/Bu and for at least 10 days for cisplatin, ovarian function did not recover naturally for 2 weeks and 1 week, respectively. Conclusions: These results suggest that CTX/Bu should be treated for at least 2 weeks and cisplatin for at least 10 days to establish the most effective primary ovarian insufficiency mouse model.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF)

References

  1. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008; 68: 499-509. https://doi.org/10.1111/j.1365-2265.2007.03073.x
  2. Norling A, Hirschberg AL, Rodriguez-Wallberg KA, Iwarsson E, Wedell A, Barbaro M. Identification of a duplication within the GDF9 gene and novel candidate genes for primary ovarian insufficiency (POI) by a customized highresolution array comparative genomic hybridization platform. Hum Reprod 2014; 29: 1818-27. https://doi.org/10.1093/humrep/deu149
  3. Cox L, Liu JH. Primary ovarian insufficiency: an update. Int J Womens Health 2014; 6: 235-43.
  4. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606-14. https://doi.org/10.1056/NEJMcp0808697
  5. Qin Y, Sun M, You L, Wei D, Sun J, Liang X, et al. ESR1, HK3 and BRSK1 gene variants are associated with both age at natural menopause and premature ovarian failure. Orphanet J Rare Dis 2012; 7: 5. https://doi.org/10.1186/1750-1172-7-5
  6. Ameratunga D, Weston G, Osianlis T, Catt J, Vollenhoven B. In vitro fertilisation (IVF) with donor eggs in post-menopausal women: are there differences in pregnancy outcomes in women with premature ovarian failure (POF) compared with women with physiological age-related menopause? J Assist Reprod Genet 2009; 26: 511-4. https://doi.org/10.1007/s10815-009-9351-5
  7. Sills ES, Brady AC, Omar AB, Walsh DJ, Salma U, Walsh AP. IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister. Reprod Biol Endocrinol 2010; 8: 31. https://doi.org/10.1186/1477-7827-8-31
  8. Hernandez-Angeles C, Castelo-Branco C. Early menopause: A hazard to a woman's health. Indian J Med Res 2016; 143: 420-7. https://doi.org/10.4103/0971-5916.184283
  9. Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: A randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016; 101: 3497-505. https://doi.org/10.1210/jc.2015-4063
  10. Slopien R, Warenik-Szymankiewicz A. Premature ovarian failure: diagnosis and treatment. Clin Exp Obstet Gynecol 2014; 41: 659-61.
  11. Sun M, Wang S, Li Y, Yu L, Gu F, Wang C, et al. Adiposederived stem cells improved mouse ovary function after chemotherapy-induced ovary failure. Stem Cell Res Ther 2013; 4: 80. https://doi.org/10.1186/scrt231
  12. Terraciano P, Garcez T, Ayres L, Durli I, Baggio M, Kuhl CP, et al. Cell therapy for chemically induced ovarian failure in mice. Stem Cells Int 2014; 2014: 720753.
  13. Lai D, Wang F, Yao X, Zhang Q, Wu X, Xiang C. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J Transl Med 2015; 13: 155. https://doi.org/10.1186/s12967-015-0516-y
  14. Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther 2017; 8: 11. https://doi.org/10.1186/s13287-016-0458-1
  15. Rebar RW. Premature ovarian “failure” in the adolescent. Ann N Y Acad Sci 2008; 1135: 138-45. https://doi.org/10.1196/annals.1429.000
  16. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update 2015; 21: 787-808. https://doi.org/10.1093/humupd/dmv036
  17. Liu TE, Wang S, Zhang L, Guo L, Yu Z, Chen C, et al. Growth hormone treatment of premature ovarian failure in a mouse model via stimulation of the Notch-1 signaling pathway. Exp Ther Med 2016; 12: 215-21. https://doi.org/10.3892/etm.2016.3326
  18. He L, Ling L, Wei T, Wang Y, Xiong Z. Ginsenoside Rg1 improves fertility and reduces ovarian pathological damages in premature ovarian failure model of mice. Exp Biol Med (Maywood) 2017; 242: 683-91. https://doi.org/10.1177/1535370217693323
  19. Jiang Y, Zhao J, Qi HJ, Li XL, Zhang SR, Song DW, et al. Accelerated ovarian aging in mice by treatment of busulfan and cyclophosphamide. J Zhejiang Univ Sci B 2013; 14: 318-24. https://doi.org/10.1631/jzus.B1200181
  20. Zhang T, Yan D, Yang Y, Ma A, Li L, Wang Z, et al. The comparison of animal models for premature ovarian failure established by several different source of inducers. Regul Toxicol Pharmacol 2016; 81: 223-32.
  21. Copelan EA, Biggs JC, Szer J, Thompson JM, Crilley P, Brodsky I, et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 1993; 20: 33-8.
  22. de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777-81. https://doi.org/10.1038/sj.bmt.1700733
  23. Han YS, Lee AR, Song HK, Choi JI, Kim JH, Kim MR, et al. Ovarian volume in Korean women with polycystic ovary syndrome and its related factors. J Menopausal Med 2017; 23: 25-31. https://doi.org/10.6118/jmm.2017.23.1.25
  24. Kim HG, Song YJ, Na YJ, Yang J, Choi OH. A rare case of an autoamputated ovary with mature cystic teratoma. J Menopausal Med 2017; 23: 74-6. https://doi.org/10.6118/jmm.2017.23.1.74

Cited by

  1. Human umbilical cord mesenchymal stem cells restore the ovarian metabolome and rescue premature ovarian insufficiency in mice vol.11, pp.1, 2018, https://doi.org/10.1186/s13287-020-01972-5
  2. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure vol.39, pp.8, 2018, https://doi.org/10.1002/cbf.3669
  3. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates vol.7, pp.1, 2018, https://doi.org/10.1038/s41421-021-00291-0